Background
Venovenous extracorporeal membrane oxygenation (VV-ECMO) should be considered when conventional mechanical ventilation failed to maintain adequate gas exchange. ECMO improved gas exchange and thus preventing hypoxia and ventilator-induced lung injury. Aim To compare between VV-ECMO and conventional mechanical ventilatory support with protective lung strategy in patients with acute respiratory distress syndrome regarding selection of patients, efficacy, complications, and outcome.
Patients and methods
We retrospectively studied 83 patients referred for VV-ECMO consideration to ECMO center in the ICU in Chest Disease Hospital in Kuwait between January 2015 and October 2018. We had two groups: ECMO group (N=38) and conventional mechanical ventilation group (control group) (N=45). We excluded from ECMO all patients with contraindication to ECMO. After 7 days, five patients shifted to rescue ECMO owing to worsening of their condition. Clinical, laboratory, ventilator parameters, complications, and survival rate were compared between both groups.
Result
The clinical, laboratory, and ventilator parameters of the patients on randomization were very bad for both groups. After 5 days, significant improvement was recorded among ECMO group. At the end point of the study, weaning from ECMO was successful in 32 (74.4%) of the 43 patients, whereas in the control group, 28 (70%) patients were weaned successfully. Mortality was nonsignificantly higher in the control group (30 vs. 25 .6% for ECMO group). The most common fatal complication among ECMO group was bleeding (63.6%), whereas it was respiratory failure among the control group (75%). Advanced age, long duration of mechanical ventilation before ECMO, immunocompromised state, higher blood lactate level and higher Acute Physiology and Chronic Health Evaluation II score, and the underlying lung disease before ECMO were associated with poor outcome. Conclusion VV-ECMO can be considered as an alternative therapy for patients with severe but potentially reversible acute respiratory distress syndrome when conventional ventilation failed. ECMO reduced the risk of ventilator-induced lung injury. ECMO significantly improved most of the clinical, laboratory, and ventilator parameters within days after ECMO application. ECMO had more favorable outcome and lower rate of mortality but with higher complications.
Introduction
Acute respiratory distress syndrome (ARDS) remains a major cause of death in the ICU. The mortality rate approaches 60% [1] . Conventional mechanical ventilatory support with intermittent positive pressure ventilation and the application of protective lung strategy remain the first-line therapy for ARDS. These protective strategies include low tidal volume, peak inspiratory pressure less than 35 cmH 2 O, high positive end-expiratory pressure (PEEP), inspiratory/ expiratory 1 : 1, and high fraction of inspired oxygen (FiO 2 ) to ensure better lung oxygenation [2] . Oxygenation of the lung is very important line of management, as it causes vasodilatation in the pulmonary vessels and accelerates the process of healing. When the conventional mechanical ventilation failed to maintain adequate gas exchange or the ventilator setting was too high that may induce volutrauma, barotrauma, or biotrauma that aggravate lung injury, an alternative treatment, venovenous (femoro-jugular) extracorporeal membrane oxygenation (VV-ECMO), was considered to provide better gas exchange. During ECMO, ventilator settings can be reduced, diminishing the potential for lung injury. This provides 'lung rest' and gives time for treatment and recovery [3] .
Aim of the work
The aim is to compare between VV-ECMO and conventional mechanical ventilatory support with protective lung strategy in patients with ARDS regarding selection of patients, efficacy, complications, and outcome.
Patients and methods and study design
Our study was applied on 83 adult patients with a confirmed diagnosis of ARDS, which was considered reversible based on the New Berlin definition of ARDS [4] . The study was approved by the institutional ethics committee at the hospitals, and all participants gave their written informed consent. They were referred to the ICU of ECMO center in chest disease hospital in Kuwait between January 2015 and October 2018. All of them fulfilled the American-European Consensus Conference definition for ARDS [5] . All of them were referred for ECMO consideration. They were reevaluated by the ECMO team and then underwent randomization; 38 were assigned for ECMO (ECMO group) and 45 for conventional mechanical ventilatory support (control group). Figure 1 illustrates our study design. It shows that 45 patients were excluded from VV-ECMO because some of them had contraindications to ECMO and the others did not fulfill the criteria of severe ARDS. After 7 days, five (11%) patients in the control group crossed over to ECMO because of refractory hypoxemia. So, the control group became 40 patients versus 43 for the ECMO group. Weaning from ECMO was successful in 32 (74.4%) of the 43 patients, whereas in the control group, 28 (70%) patients weaned successfully. Disease severity was assessed using Acute Physiology and Chronic Health Evaluation (APACHE II) score [6] . Severe ARDS was defined as a Murray score more than or equal to 3.0, or uncompensated hypercapnia with a pH less than 7.20 [7] . The referring intensivist discussed the trial with the patient's relatives, and written consent for agreement to the trial was taken.
The end point in our study was either death or improvement and weaning.
Inclusion criteria of patients connected to venovenous extracorporeal membrane oxygenation were as follows:
(1) Patients age more than 18 years.
(2) Severe ARDS due to reversible etiology with partial pressure of arterial oxygen (PaO 2 )/FiO 2 less than 80 while the patient was receiving FiO 2 more than 90%, PEEP (15-20 cmH 2 O), and Murray score more than or equal to 3. (3) pH less than 7.25 despite optimization of the ventilator settings.
Exclusion criteria for venovenous extracorporeal membrane oxygenation were as follows:
( Conventional means relying on the patient's lungs to maintain gas exchange. Patients randomized to conventional ventilatory support received low-volume low-pressure ventilation with protective lung strategy according to the ARDS Network group. These protective strategies included low tidal volume (4-8 ml/kg), FiO 2 adjusted to maintain SaO 2 more than 90% and to keep the peak airway pressure less than 35 cmH 2 O, plateau pressure less than 30 cmH 2 O, ventilator rate (20-25/min), and PEEP 10-15 cmH 2 O [8] . The ventilator sittings were adjusted according to arterial blood gas (ABG) measurements. Continuous observation of vitals was done by a pulse oximeter. Other protective strategies were applied to prevent ventilator-associated pneumonia (VAP), such as keeping the patient in a semisitting position and early nasogastric feeding. The reliance on the patient's lungs to maintain gas exchange, especially with high airway pressures, eliminated any possibility for lung rest. Any patient who developed deterioration on mechanical ventilation or developed severe ARDS was shifted to ECMO.
The extracorporeal membrane oxygenation group
During ECMO, blood is drained from the right common femoral vein and reinfused through the right internal jugular vein. The blood circulated outside the body by a mechanical pump to pass through an oxygenator where full oxygen saturation and CO 2 removal occur [9] . Unfractionated heparin was infused by continuous intravenous infusion and maintained during ECMO to avoid clot formation in the oxygenator membrane, with targeting the activated clotting time to be 160-210 s, or activated partialthromboplastin time to be 40-55 s. If the patient developed heparin-induced thrombocytopenia, heparin will be replaced by bivalirudin (R/ Angiomax). During ECMO, platelets were continuously consumed as they were exposed to the foreign surface area of the oxygenator. This may require platelet transfusion to maintain platelet count more than 50 000/μli [10] . During ECMO, pressurecontrolled ventilation was used, and ventilator settings were reduced to avoid oxygen toxicity and ventilatorinduced lung injury and to allow lung rest, which helps in recovery. Plateau pressure should be maintained less than 20 cmH 2 O peak airway pressure less than 25 cmH 2 O, FiO 2 less than 30%, PEEP 5 cmH 2 O, respiratory rate 5-10 breaths/min, and VT 3-4 ml/ kg. Mechanical ventilation on ECMO aimed to keep the lung open than to provide oxygen [11] . In ECMO settings, there were three main variables that should be adjusted to achieve the desirable levels of oxygen saturation and carbon dioxide removal. These variables were the pump flow, oxygen fraction in the sweep gas, and the sweep gas flow rate. The pump delivered the venous blood from the patient to the oxygenator. The greater the pump flow, the greater the oxygen delivery. The second variable was to increase oxygen fraction in the sweep gas to increase the partial pressure of oxygen in the blood. The third variable was the sweep gas flow rate. Increasing the sweep gas flow rate led to more oxygenation and carbon dioxide elimination across the semipermeable membrane.
The followings were monitored during ECMO:
(1) ABGs.
(2) Blood gases in the ECMO circuit before and after going through the oxygenator to monitor the efficacy of the oxygenator membrane. The therapeutic target for ECMO was to achieve PaO 2 more than or equal to 60 mmHg or SaO 2 more than or equal to 90% on FiO 2 less than 50% and pH more than or equal to 7.25. When the patient was able to maintain adequate gas exchange with improvement of lung compliance and chest radiography on minimal ventilator settings, then patients could be weaned from ECMO [12] .
Statistical analysis
All statistical analyses were carried out using SPSS software version 16.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were presented as mean and SD, whereas dichotomous variables were described as numbers and percentages. For comparisons between groups at each time point, unpaired t test was used for normally distributed variables. Mann-Whitney U test was used to compare continuous variables. Frequencies were generated for categorical variables and compared with the chi-square test. P value less than 0.05 was considered statistically significant.
Results
Eligible patients aged 18-75 years with reversible causes of ARDS were included. As shown in (Table 1) , Murray score was calculated to assess ARDS severity index for patient selection. Patients with severe ARDS were referred to ECMO. The baseline characteristics, clinical features, and laboratory and ventilator parameters of the two groups (on randomization) are presented in ( Table 2) . We had 38 patients randomized to ECMO and 45 patients for conventional mechanical ventilation. The main causes of ARDS in both groups were bacterial pneumonia, viral pneumonia, and after trauma or surgery. The ECMO group showed significantly higher Murray score (3.9±0.5 vs. 2.7 ±0.4), lower Glasgow coma score (8.9±1.8 vs. 10.4 ±1.2), lower mean arterial pressure values (63.2±3.4 vs. 79.6±5.3 mmHg), and higher percentage of patients on vasopressor (39.5 vs. 17.8%) for the control group. The characteristics of the patients at baseline (randomization) were similar in the two groups because both of them were critically ill, but ECMO group exhibited higher APACHE II score, worse ABG parameters, and worse clinical, laboratory, and ventilator parameters (but without statistical significance). As shown in (Table 3) , ECMO group exhibited significant improvement in Murray score, APACHE II score, ABG parameters, oxygenation index, and clinical and laboratory parameters after 5 days from randomization. Table 4 showed nonsignificant higher total duration of mechanical ventilation in the control group (15.7±4.8). The mean duration of VV-ECMO was 9.5±3.5 days. A significant higher length of ICU and hospital stay was Graded 0-4 to give a severity index for acute respiratory distress syndrome. The Murray score is calculated by taking the score for each variable and dividing by 4. FiO 2 , fraction of inspired oxygen; PaO 2 , partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.
documented in the ECMO group. There were significant higher percentages of complications among ECMO group mostly related to ECMO device. The major ECMO-related complications were thrombocytopenia, bleeding, renal dysfunction, and septic shock (60.5, 34.9, 30.2, and 20.9%, respectively), whereas VAP was the most common complication among the control group. Mortality was nonsignificantly higher in the control group (30 vs. 25 .6% for ECMO group). Table 5 shows the cause of death among both groups. Seven patients in the ECMO group died from severe bleeding; one of them developed hemorrhagic stroke. Five patients died from respiratory failure; three of them also developed fatal septic shock. Two patients developed thrombosis and embolization. The main causes of death in the control group were respiratory failure overlapped with MOF and septic shock secondary to VAP. Table 6 shows the comparison between survivors and nonsurvivors among both groups. ECMO group exhibited higher survival rates and lower death rates than did the control group. Chronic obstructive pulmonary disease was the most prevalent underlying lung disease among nonsurvivors in both groups. Nonsurvivors were significantly older, were more immunocompromised with a significant higher APACHE II score, and had a significant longer duration of ventilation before randomization among both groups. Values are described as mean±SE or n (%). APACHE II, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; ECMO, extracorporeal membrane oxygenation; FiO 2 , fraction of inspired oxygen; GCS, Glasgow coma score; LDH, lactate dehydrogenase; MAP, mean arterial pressure; NA, Not applicable; PaCO 2 , partial pressure of arterial carbon dioxide; PaO 2 , partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure; SaO2, arterial oxygen saturation; WBC, white blood cell. *significant P value.
Discussion
ECMO is now considered as a standard therapeutic option for patients with severe ARDS when conventional mechanical ventilation fails to improve the critical situation of the patients and also to minimize ventilator-induced lung injury [13] . As shown in (Figure 1) , we had 83 patients with ARDS referred to ECMO center for VV-ECMO; 38 patients were assigned to VV-ECMO group, as they fulfilled the criteria of severe ARDS according to Murray score, and 45 patients were continued on mechanical ventilation with protective lung strategies (control group). As shown in (Table 2) , our results revealed no big differences between both groups regarding the clinical, laboratory, and the ventilator parameters, as both groups were critically ill. Patients assigned to ECMO fulfilled the criteria of severe ARDS, so their parameters were worse, especially regarding the mean arterial pressure, Glasgow coma score, Murray score, and the number of shocked patients needing vasopressors. By comparing the results of both groups after 5 days of randomization, there was significant improvement in ABG, Murray score, APACHE II score, oxygenation index, total leukocytic count, and body temperature among ECMO group compared with the control group (Table 3 ). This can be explained by better tissue oxygenation after ECMO, with improved systemic immunity, which controls inflammation. Our results were consistent with that found by Allam [14] who recorded significant improvement in oxygen saturation, hypoxic index, and lung compliance after ECMO application. Wu et al. [15] also found marked improvement in oxygenation and general condition in the ECMO group but with higher mortality. We noticed that serum lactate levels (taken as a marker of tissue perfusion) decreased significantly 5 days after ECMO, as also recorded by Biscotti et al. [16] . We also found a significant reduction in the inflammatory markers such as lactate dehydrogenase and Creactive protein levels in ECMO group compared with control group. The same findings were recorded by Bajwa et al. [17] . Our results noticed acute renal dysfunction requiring dialysis among ECMO group, reflected as elevation of serum creatinine and low urine output. The same findings were also recorded by Chen et al. [18] . Despite the use of protective lung strategies, five patients in the control group crossed over to ECMO after 1 week from randomization owing to progressive clinical deterioration with refractory hypoxemia (PaO 2 /FiO 2 ratio <80 on FiO 2 >90%, SaO 2 of <80% for >6 h) with uncompensated hypercapnia and acidosis pH less than 7.20, and persistent or progressive new pulmonary infiltrates on chest radiograph [19] . At the end point of the study, we noticed no big difference between both groups regarding the duration of mechanical ventilation before randomization (Table 4 ). We noticed that the mean duration of ventilation before ECMO was short. Other studies showed that the longer the duration of mechanical ventilation before ECMO, the worse outcome and higher mortality [20] . Our results showed significant longer duration of ICU and hospital stay in ECMO group than in control group. This could be explained by the more severe clinical situation of the ECMO group. Similar results were found by Szentgyorgyi et al. [21] , as they recorded that the median length of hospital and ICU stay was significantly longer in ECMO group. Life-threatening complications were frequent among ECMO group. The most frequent complication recorded was bleeding (34.9%), which required blood transfusion (gastrointestinal hemorrhage occurred in nine patients and intracerebral hemorrhage occurred in six patients). This could be attributed to the systemic effect of heparin. Similar results were recorded by Del Sorbo et al. [22] . A total of 26 patients developed thrombocytopenia, nine patients developed septic shock, and 13 patients developed renal dysfunction and required renal replacement therapy. Seven patients developed thrombosis; three of them complicated with embolization. Despite the aforementioned complications, the outcome of ECMO was better than that in the control group. The percentage of nonsurvival on ECMO was slightly lower than in the control group and mostly attributed to the hemorrhagic complications of ECMO. The same results were reported by Schmidt et al. [23] . Despite the protective strategies, VAP was the most frequent complication (42.5%) in our control group. Similar results also reported by Patroniti et al. [24] . Many causes overlapped together to cause death in both groups, as shown in (Table 5 ). Bleeding was the most frequent fatal complication among ECMO group, whereas respiratory failure with septic shock was the most frequent in control group. These findings were consistent with that found by Peek et al. [25] . We found that older age, immunocompromised state, longer duration of ventilation before randomization, and advanced stage of the underlying lung disease increased the mortality rate in both groups. In our study, we had three patients with ARDS with lung fibrosis in the ECMO group; two patients died, and the one who survived was planned for lung transplantation. This result suggested the proper selection of candidates for ECMO. Patients with irreversible underlying lung diseases such as fibrosed lungs should not be considered for ECMO except if ECMO was applied as a bridge for lung transplantation as also reported by Liu et al. [26] . In our study, the duration of mechanical ventilation before ECMO was significantly lower in survivors than nonsurvivors. According to the established protocol, 7-day duration of ventilation before ECMO was considered as a cut-off point, and more than 7-day ventilation time was taken as an exclusion criterion for ECMO [1] . However, according to the new criteria based on Extracorporeal Life Support Organization guidelines, the duration of mechanical ventilation was no longer associated with mortality in the recently treated patients [27] . Schmidt et al. [28] reported that early initiation of ECMO improved survival. Other studies reported that the longer duration of mechanical ventilation before ECMO was associated with higher mortality [29] . This could be explained by that the prolonged duration of ventilation before ECMO increased the possibility of developing irreversible ventilatorinduced lung injury. Other studies reported that advanced age, more critically ill situation with high APACHE II score, and multiple organ dysfunctions were also associated with poor outcomes and higher mortality. Tsai et al. [30] reported high APACHE II score as an indicator for nonsurvival. We found that lactate levels (taken as a marker of tissue perfusion) of the nonsurvivors were higher than those of the survivors in ECMO group, suggesting that ECMO may be less useful to control severe ARDS with septic shock [26] .
Other studies reported the successful use of ECMO on patients with severe influenza-associated ARDS with favorable outcome [31] .
Conclusion
VV-ECMO can be considered as an alternative therapy for patients with severe but potentially reversible ARDS when conventional ventilation fails. ECMO reduced the risk of ventilator-induced lung injury. ECMO significantly improved most of the clinical, laboratory, and ventilator parameters within days after ECMO application. ECMO had more favorable outcome and lower rate of mortality but with higher complications.
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